Submodule
Nephron Transport and Diuretic Response
A diuretic can work only after reaching its target. Filtered load, tubular secretion, protein binding, renal perfusion, transporter capacity, and downstream compensation shape response.
- Segmental sodium handling
- Tubular secretion
- Distal sodium delivery
- Volume and neurohormonal compensation
Bicarbonate and water handling
High-capacity salt and divalent cation effects
Moderate sodium loss and calcium retention
Potassium and acid secretion
Use segment capacity
The proximal tubule reabsorbs a large filtered sodium fraction, the thick ascending limb has high transport capacity, and later segments fine-tune sodium balance. Blocking a high-capacity segment usually creates greater natriuresis, while downstream segments can reclaim part of the delivered sodium.
Deliver drug to the lumen
Most loop and thiazide diuretics are highly protein bound and reach luminal transporters through proximal tubular organic anion secretion rather than unrestricted filtration. Reduced renal perfusion, competing organic acids, kidney disease, and impaired absorption can reduce target-site exposure.
Predict potassium and acid-base effects
Greater sodium delivery to the collecting duct supports epithelial sodium channel entry and creates electrical and hormonal conditions for potassium and hydrogen secretion. Loop and thiazide therapy can therefore produce hypokalemic metabolic alkalosis, especially with volume contraction and aldosterone activation.
Separate weight loss from safe decongestion
A lower scale value may reflect effective removal of excess extracellular fluid or harmful loss of effective circulating volume. Interpret weight with symptoms, edema, jugular venous pressure, lung findings, blood pressure, perfusion, urine response, kidney function, and electrolyte trend.
Quick check
Submodule
Loop Diuretics
Furosemide, bumetanide, torsemide, and ethacrynic acid inhibit NKCC2 in the thick ascending limb, producing high-capacity natriuresis and disrupting the medullary concentration gradient.
- NKCC2 inhibition
- Loop agent differences
- Electrolyte and mineral loss
- Ototoxicity and acute response
Na, K, and Cl reabsorption fall
Water excretion changes
Calcium and magnesium losses rise
Dose, rate, kidney function, interactions
Block NKCC2
Loop diuretics inhibit the sodium potassium two-chloride cotransporter in the thick ascending limb. Sodium chloride reabsorption and the lumen-positive voltage fall, increasing downstream sodium delivery and urinary potassium, calcium, and magnesium loss.
Distinguish molecules and formulations
Furosemide oral absorption can be variable, while bumetanide and torsemide have different potency and exposure profiles. Ethacrynic acid lacks the common sulfonamide group but still has major toxicity concerns. Dose conversion is approximate and must be tied to response.
Monitor volume and electrolyte cost
Excessive diuresis can cause hypotension, reduced perfusion, rising kidney indices, hyponatremia, hypokalemia, hypomagnesemia, and metabolic alkalosis. Digoxin, corticosteroids, laxatives, and other electrolyte-altering therapies can increase consequences.
Protect hearing and tissue
Loop-associated ototoxicity is more likely with rapid parenteral administration, high exposure, severe kidney impairment, hypoproteinemia, or another ototoxic agent such as an aminoglycoside. Follow the exact product rate, concentration, access, and monitoring requirements.
Quick check
Submodule
Thiazide and Thiazide-Like Diuretics
Hydrochlorothiazide, chlorthalidone, indapamide, and metolazone inhibit NCC in the distal convoluted tubule, with meaningful differences in duration, evidence, and use during reduced kidney function.
- NCC inhibition
- Calcium retention
- Hyponatremia and hypokalemia
- Metabolic and interaction effects
Distal sodium delivery rises
Hypokalemic alkalosis risk
Distinct from loop effect
Monitor patient-specific risk
Block NCC
Thiazide and thiazide-like drugs inhibit the sodium chloride cotransporter in the distal convoluted tubule. Their natriuretic ceiling is lower than loop therapy, but longer action and vascular adaptation make selected products useful for chronic blood pressure control.
Reverse the loop calcium pattern
NCC inhibition favors distal calcium reabsorption and can reduce urinary calcium. This differs from loop diuretics. The effect can be useful in selected calcium-stone contexts but can also contribute to hypercalcemia in susceptible patients.
Recognize sodium and potassium risk
Hyponatremia may be severe, especially in older adults, patients with low solute intake, small body size, high water intake, or interacting medicines. Hypokalemia and metabolic alkalosis reflect distal sodium delivery and aldosterone-supported secretion.
Audit urate, glucose, lithium, and NSAIDs
Thiazide-like therapy can raise uric acid and affect glucose tolerance. Sodium depletion can reduce lithium clearance and cause toxicity. Nonsteroidal anti-inflammatory drugs can blunt the renal response and worsen kidney risk in susceptible patients.
Quick check
Submodule
Potassium-Sparing Diuretics
Mineralocorticoid receptor antagonists reduce aldosterone signaling, while amiloride and triamterene block ENaC directly. Both reduce potassium and hydrogen secretion but differ in onset and nonrenal pharmacology.
- Spironolactone and eplerenone
- Amiloride and triamterene
- Hyperkalemia and acidosis
- Endocrine and interaction effects
Slow genomic antagonism
CYP3A exposure matters
Direct luminal action
Kidney function and regimen burden
Block aldosterone signaling
Spironolactone and eplerenone antagonize intracellular mineralocorticoid receptors, reducing ENaC and sodium potassium ATPase expression over time. Their clinical value can extend beyond weak natriuresis because mineralocorticoid signaling affects cardiovascular remodeling.
Block ENaC directly
Amiloride and triamterene act at the luminal epithelial sodium channel in the collecting duct. Amiloride has specific value when excessive ENaC activity is central, while product and indication determine its broader use. Direct channel block acts without waiting for receptor-mediated gene expression.
Protect against hyperkalemia
Reduced sodium entry lowers the electrical drive for potassium and hydrogen secretion. Hyperkalemia and non-anion-gap metabolic acidosis become more likely with kidney impairment, diabetes, high potassium intake, supplements, salt substitutes, RAAS blockers, or another potassium-sparing agent.
Distinguish endocrine and metabolic profiles
Spironolactone can interact with androgen and progesterone pathways, causing gynecomastia, breast symptoms, sexual effects, or menstrual changes. Eplerenone is more receptor selective but has important CYP3A interaction constraints. Monitor by the exact product.
Quick check
Submodule
Carbonic Anhydrase, Osmotic, Aquaretic, and Proximal Agents
Acetazolamide, mannitol, vasopressin antagonists, and SGLT2 inhibitors alter different solutes or water pathways and should not be treated as interchangeable volume drugs.
- Acetazolamide
- Mannitol
- Vasopressin V2 antagonism
- SGLT2 inhibition
Bicarbonaturia and acidosis
Compartment shifts before excretion
Electrolyte-free water excretion
Modest natriuresis within broader outcomes
Use acetazolamide to produce bicarbonaturia
Carbonic anhydrase inhibition reduces proximal bicarbonate reclamation and can produce alkaline urine with hyperchloremic metabolic acidosis, hypokalemia, and reduced effectiveness after bicarbonate stores fall. Product-specific uses extend beyond edema to ocular, neurologic, and altitude contexts.
Respect mannitol compartment shifts
Mannitol is filtered and poorly reabsorbed, increasing tubular fluid osmolality. Before excretion, intravenous osmotic expansion can worsen pulmonary congestion or hyponatremia in susceptible patients. Later water loss can produce hypernatremia and hypovolemia if replacement is inadequate.
Distinguish aquaresis from natriuresis
Vasopressin V2 antagonism reduces collecting-duct water permeability and increases electrolyte-free water excretion. Serum sodium can rise rapidly, so diagnosis, baseline sodium, access to water, liver considerations, and product-specific initiation requirements are essential.
Place SGLT2 inhibition in a broader outcomes model
SGLT2 inhibitors reduce proximal glucose and sodium reabsorption and produce modest osmotic and natriuretic effects. Their cardiovascular and kidney benefits cannot be explained as simple diuresis alone. Volume status, genital infections, ketoacidosis risk, kidney function, and peri-procedure holding plans remain important.
Quick check
Submodule
Clinical Selection, Resistance, and Monitoring
A poor response can reflect inadequate delivery, impaired absorption, reduced renal perfusion, low target-site secretion, excess sodium intake, post-diuretic retention, or nephron adaptation.
- Objective response
- Diuretic resistance
- Sequential nephron blockade
- Monitoring and deprescribing
Drug must reach the tubular lumen
Early objective effect
Post-diuretic retention and resistance
Perfusion and electrolyte safety
Measure early response
Urine output and urinary sodium after dosing can provide earlier evidence of natriuretic response than next-day weight. Pair them with symptoms, physical examination, fluid balance, pressure, perfusion, and the clinical goal. No isolated marker defines successful decongestion.
Reconstruct resistance
Edema can impair oral absorption. Kidney disease can reduce tubular secretion and increase competing organic acids. High sodium intake and short drug exposure can cause post-diuretic sodium retention. Chronic distal nephron adaptation can reclaim more sodium after loop blockade.
Use sequential blockade deliberately
Adding a thiazide-like agent to loop therapy can block distal sodium recovery and produce powerful natriuresis. It can also cause severe hyponatremia, hypokalemia, hypomagnesemia, alkalosis, hypotension, and kidney dysfunction. Timing and laboratory surveillance must follow protocol.
Reassess the maintenance need
After congestion resolves or the precipitating condition changes, the required diuretic dose may fall. Continue outcome-directed therapies for their validated indications, but avoid maintaining a volume-removal dose solely because it was once needed. Adjust through clinician-guided follow-up.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.